Market Place
Sourcing Support
Novadip’s NVDX3 Reaches Milestones for IND Approval in Spine Fusion
20 Nov 2024 //
PHARMAWEB
Novadip Announces First Pediatric Patient Undergoes Implantation with NVD-003
17 May 2023 //
BUSINESSWIRE
Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer
27 Dec 2022 //
BUSINESSWIRE
Novadip reveals results from severe bone non-union trial
09 Dec 2022 //
PHARMATIMES
Novadip Announces Results from Phase 1/2 Trial with Non-Union of Lower Limb
08 Dec 2022 //
BUSINESSWIRE
Novadip Raises Additional EUR 40 M Bringing Total Company Funding to EUR 88 M
03 Nov 2022 //
BUSINESSWIRE
Novadip Biosciences announces EUR 19 million Series B financing
27 Oct 2021 //
GLOBENEWSWIRE
Bone regeneration stem cell “putty” sees positive results in trials
15 Jun 2021 //
PHARMAFILE
Novadip reports positive data from phase I study of NVD-001 for spinal fusion
15 Jun 2021 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.